First Horizon Corporation’s Cytokinetics CYTK Stock Holding History

First Horizon Corporation’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8K	Hold	127	–	–	﹤0.01%	1092
2026 Q1	$8.37K	Hold	127	–	–	﹤0.01%	1093
2025 Q4	$8.07K	Hold	127	–	–	﹤0.01%	1155
2025 Q3	$6.98K	Buy	+127	New	+$5.23K	﹤0.01%	1135
2021 Q2	$0	Hold	17	–	–	﹤0.01%	1097
2021 Q1	$0	Buy	+17	New	+$363	﹤0.01%	1082

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Horizon Corporation's CYTK Position: Q2 2026 in Review

First Horizon Corporation held its Cytokinetics (CYTK) position steady in Q2 2026 at 127 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

First Horizon Corporation first reported a position in CYTK in Q1 2021 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

First Horizon Corporation held 127 shares of Cytokinetics worth $10.8K as of Q2 2026.
First Horizon Corporation left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #1092 holding.
First Horizon Corporation first reported a position in Cytokinetics in Q1 2021 and has held it in 6 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.